Convergent Bragg Lens
Proprietary radiation delivery technology
The Convergent Bragg Lens generates a therapeutic radiation beam from a kilovoltage (kV) source, enabling dose deposition at depth while minimizing skin exposure. This approach produces dose characteristics comparable to proton delivery systems that leverage the Bragg Peak, but with the potential for significantly lower infrastructure complexity and cost.
Convergent Bragg Lens
V3.0
Focal Width (FWHM)
3.6mm
Focal Length (FWHM)
34mm
*Measured in air
This capability we call the Convergent MiniBeam expands the applicability of SFRT to medium and small tumors while providing researchers with a powerful tool to evaluate immunotherapy compounds across emerging disease cell types.
Importantly, the technology may help convert immunologically “cold” tumors into more responsive phenotypes, positioning SFRT as a potential neoadjuvant strategy to enhance the effectiveness of immunotherapy.
Additional versions and variations under development
Depth Dose Distributions in Water
Convergent Bragg Lens converts a kilovoltage source into a therapeutic beam with Bragg-peak-like dose deposition.
Collimation versus Convergence
Dose distribution
At Convergent RnR, our innovative approach utilizes a proprietary, patented Convergent Bragg Lens to drastically reduce damage to healthy tissue. This technology delivers superior accuracy, unlocking effective treatment options even for smaller tumors and previously untreatable conditions.
Most conventional radiotherapy systems include radiation sources that produce diverging radiation beams that must then be collimated to achieve the correct target distribution. This divergence introduces a dose gradient that decreases with distance from the source.
A low-energy parallel kilovoltage (kV) photon beam would result in significant attenuation at a depth of only a few cm, and relatively strong dose at shallow depths (that results in skin toxicity). For this reason, such low energies are not used in radiotherapy or radiosurgery.
Our Convergent Bragg Lens overcomes this problem, allowing the use of energies that are lower than conventional linear accelerators (LINAC) and the use of X-ray sources that are typically relegated to diagnostic imaging. Consequently, installation is simplified by eliminating the requirement for cost-prohibitive shielding or specialized radiation bunkers.
Convergent Bragg Lens radiotherapy utilizes highly focused X-ray beams to produce an exceptionally steep dose gradient (skin sparing), enabling precise dose placement within highly localized regions. By sparing healthy tissue from inadvertent radiation, this innovative approach is designed to optimize local control, potentially downstaging aggressive tumors to make them resectable, and guiding patients toward a Complete Response (CR) and a state of No Evidence of Disease (NED).
Ultimately, this precision aims to enhance both the durability of response and Progression-Free Survival (PFS), protecting patients from late recurrence and extending Overall Survival (OS).